PROTOCOL  
 
STUDY NUMBER:   INDV -6000- 404 
 
PROTOCOL TITLE:   An Open -label treatment extension study for eh Rapid Initiation of Extended -
Release Buprenorphine Subcutaneous Injection (SUBLOCADE ™) 
 
NCT NUMBER:   [STUDY_ID_REMOVED] 
 DATE:    04Dec2019  
  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 1 of 52 
 
 
   
   
 16.1.1 CLINICAL RE SEARCH PROTOCOL 
DRUG: SUBLOCADE™ (extended-release 
buprenorphine) 
STUDY NUMBER: INDV-6000-404 
PROTOCOL TITLE: An Open-label , treatment extension study for 
the Rapid Initiation of Extended-Release 
Buprenorphine Subcutaneous Injection  
(SUBLOCADE™) 
SHORT TITLE: SUBLOCADE Rapid Initiation Extension Stud y 
IND NUMBER: 107,607 
PHASE: IV 
SPONSOR:  
Indivior Inc. 
10710 Midlothian Turnpike, Suite 125 
North Chesterfield, VA 23235 
USA 
ORIGINAL PROTOCOL 
DATE: 07 August 2019 
 
PROTOCOL AMENDMENT 1 
DATE: 04 December 2019 
 
 
 
Confidentiality Statem
ent 
This document is a confidential communication of Indivior. The recipient agrees that no 
unpublished information contained herein will be published or disc losed without prior 
written approval of Indivior, ex cept that this document may be disclosed to appropriate 
ethics committees or duly authorized representatives of the US Food and Drug 
Administration or other respons ible Regulatory Authorities under the condition that they are 
requested to keep it confidential.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 4 of 52 
 
 
   
   
 SUMMARY OF CHANGES 
 
 Change Section  
Affected  Sum
mary of Change(s) 
1.  Number of subjects 
increased from up to 15, 
to 25.  Section 4.1 
Section 5.1 
Section 14.2 
 Number of subjects increased to account for 
additional subjects enrolled onto INDV-6000-
403 stu d
y.  
2.  Concomitant medications 
or indications for such, 
will not be coded or 
su
mmarized. Section 13.1 
Section 14.4 .3 Concomitant medications are required to be 
listed only fo
r this study.  
3.  Detox and MOUD history
 
will be collected and 
summarized.  Section 4.1 
Section 4,2  
Section 8.1 
Section 14.4.3 
 This will be collected retrospectively for 
subjects enrolled in the study at the time
 of 
this amendment.  
4.  Added that the safety
 
population will be the 
primary population for all 
analyses. Section 14.3 The safety population was defined but 
utilization for analy ses not stated. 
5.   Typographical error 
corrected. Section 4.2  Injection 3 Vi
sit, corrected to “Visit 3”  
6.  Typographical error 
corrected. Section 9.8 Subjects do not “check-in” to the clinic on 
day 1, therefore text updated to state subjects 
abstain from
 alcohol throu
ghout the study. 
 
  
16.1.1 Protocol Amendment 1 
INDV-6000-404
 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extende
d-release buprenorphine) Pa ge 5 of 52 
 
 
   
   
  
STUDY PERSONNEL INFORMATION 
 
Medica l Monitor: 
(24-hour coverage)  
 
   
Back-up Medical 
Monitor  
 
 
  
  
 
   

16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 6 of 52 
 
 
   
   
  
STUDY SUMMARY 
Protocol 
Number: INDV-6000-404 
Title:  An Open-label, treatment extensi on study for the Rapid Initiation of 
Extended-Release Buprenorphine Subcutaneous Injection 
(SUBLOCADE™) 
Rationale:  This study (INDV-6000-404) is to provide ongoing treatm ent with 
SUBLOCADE for up to 5 additional inje ctions and safety monitoring for 
subjects who initiated SUBLOC ADE following a single dose of 
transm
ucosal (TM) buprenorphine in stud y INDV-6000-403. 
Target 
Population: Subjects with moderate or severe opioid use disorder (OUD) who are 
seeking medication for OUD (MOUD) and have completed INDV-6000-
403 stud y.  
Number of 
Subjects: Up to 25 adult subjects 
Objective:  The objective of this study is to as sess the longer-term safety of an 
abbreviated initiation protocol of SUBLOCADE in subjects who have 
completed INDV-6000-403.  It is also to provide treatment to these 
individuals while they seek longe r-term care arrangements, as it (on 
average) takes an individual with OUD 6 m
onths between seeking treatment 
and achievin g an appointment at a provider within the US.  
Study Design:   
Only subjects who have completed the End of Treatment (EOT) procedures 
for Study INDV-6000-403, have signed the INDV-6000-404 informed 
consent form (ICF), and meet all the enrollme
nt criteria may be considered 
for inclusion in this study.  
 
The INDV-6000-403 EOT visit is 28 days after the subject’s first dose of 
SUBLOCADE in INDV-6000-403, ther efore the INDV-6000-403 EOT and 
the INDV-6000-404 screening and Day 1 visit for this study will occur 
within 2 days, thus the INDV-6000-403 EOT assessments will serve as the 
screening assessments for the Screen ing Visit (Day 1) of this study.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 7 of 52 
 
 
   
   
 Any AEs and concomitant medi cations ongoing at the INDV-6000-403 
EOT will be re-recorded fo r this stud
y. In addition, demographics, height, 
medical/psychiatric, substance and dr ug of abuse history will not be re-
collected and will be taken from the INDV-6000-403 screening 
assessments.  A detailed detox a nd MOUD treatment history will be 
collected at screening. For those subj ects who have enrolled in the study 
prior to approval of protocol amendment 1, their detox and MOUD 
treatment history will be collected re trospectively at th eir next visit. 
 
On Day 1, eligible subjects will receive a SC injection of 300mg 
SUBLOCADE. Before departing the site , any new adverse events (AEs) or 
concomitant medications will be recorded. 
 
Subjects will return to the site for monthly injection visits every 4 weeks (-2 
/ +7 days) for a total of up to 5 inj ections. At Injection Visits 2 through 5, 
subjects will be evaluated in accordance with local standard of care and 
results for the following procedures w ill be recorded: urine pregnancy test 
(to be performed before SUBLOCAD E administration for all female 
subjects who are of childbearing pote ntial); urine drug screen (UDS) and 
evaluation of previous injection site  for potential reaction and evidence of 
attempts to remove the depot. For inj ections 2 to 5, subjects may receive 
either a dose of 100 mg SUBLOCAD E or 300 mg SUBLOCADE, based on 
the medical judgment of th e Investigator, per the SUBLOCADE USPI . 
During each  visit the subject will be assessed for AEs and use of 
concomitant medications.  
All subjects will receive  counselling as determ
ined by local standard of care 
throughout the study from  Day 1 through EOT. 
All subjects who receive SUBLOCAD E (including those who wish to 
discontinue early), will be encouraged to attend the EOT/ET visit 4 weeks 
after SUBLOCADE administration.  
At the EOT/ET Visit, results for the following procedures and assessments 
will be recorded:  urine pregnancy test  for all female subjects who are of 
childbearing potential; evaluation of pr evious injection site for potential 
reaction and evidence of attempts to remove the depot; UDS; use of 
concomitant medications and assessment for AEs. At every Visit options for 
continued care should be di scussed with the subject. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 8 of 52 
 
 
   
   
 Any subject with ongoing AEs or concom itant medications at the EOT Visit 
will also be followed up by telephone 4 weeks later for a safety follow up to 
assess the ongoing AEs or concomitant medications only. 
 
Primary 
Endpoint:  The proportion of subjects with treatmen t em
ergent adverse events (TEAEs) 
at an y time durin g the treatment perio d.  
Other Safety 
Assessments:  Additional safety endpoints will in clude assessment of: drug-related 
TEAEs, serious TEAEs, drug-related se rious TEAEs, TEAEs leading to 
treatment discontinuation and conco
mitant medications. 
 
   
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 9 of 52 
 
 
   
   
 TABLE OF CONTENTS 
1 INTRODUCTION AND RATIONALE .................................................................14  
1.1  Background ..........................................................................................................14  
1.2  Study Rationale ....................................................................................................14  
1.2.1  Dosing Regimen  ..............................................................................................14  
1.3  Risk-Benefit Assessment ......................................................................................15  
1.3.1  Risk Assessment .............................................................................................15  
1.3.2  Benefit Assessment .........................................................................................15  
1.3.3  Overall Risk-Benefit S ummary ....................................................................16  
2 STUDY OBJECTIVE ...............................................................................................17  
3 STUDY ENDPOINTS ..............................................................................................18  
3.1  Primary .................................................................................................................18  
3.2  Other Safety Assessments....................................................................................18  
4 STUDY PLAN ...........................................................................................................19  
4.1  Study Design .........................................................................................................19  
4.2  Schedule of Assessmen ts ......................................................................................20  
5 POPULATION ..........................................................................................................23  
5.1  Number of Subjects..............................................................................................23  
5.2  Inclusion Criteria .................................................................................................23  
5.3  Exclusion Criteria ................................................................................................23  
5.4  Subject Screening .................................................................................................23  
5.5  Deviation from Inclusio n/Exclusion Criteria ....................................................23  
6 STUDY CONDUCT ..................................................................................................24  
6.1  Subject Screening .................................................................................................24  
6.2  Enrolled .................................................................................................................24  
6.3  Not Enrolled .........................................................................................................24  
6.4  Treatment Period  .................................................................................................24  
6.5  Treatment Period Completion ............................................................................24  
6.6  Study Completion .................................................................................................24  
6.7  Early Termination  ...............................................................................................25  
6.8  Withdrawal and Stopping Criteria ....................................................................25  
6.8.1   Subject Withdrawal from the Study ............................................................25  
6.8.2   Subject Withdrawal of Consent ....................................................................25  
6.8.3   Subjects Lost to Follow-up ............................................................................25  
7 STUDY SUSPENSION OR TERM INATION .......................................................26  
8 DESCRIPTION OF STUDY PROCEDURES .......................................................26  
8.1  Demographics and Medical/Psychiatric History ...............................................26  
8.2  Safety Assessments ...............................................................................................26  
8.2.1   Clinical Laboratory Tests..............................................................................26  
8.2.1.1  Urine Drug Screening (UDS)  ..................................................................27  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 10 of 52 
 
 
   
   
 8.2.1.2   Urine Pregnancy Test ..............................................................................27  
8.2.2  Injection site Evaluation ................................................................................27  
8.3  Protocol Deviations ..............................................................................................27  
9 STUDY DRUG MANAGEMENT ...........................................................................28  
9.1  Description  ............................................................................................................28  
9.1.1  Formulation ....................................................................................................28  
9.1.2  Storage ............................................................................................................28  
9.2  Packaging and Labelling .....................................................................................28  
9.3  Shipment ...............................................................................................................29  
9.4  Dose and Administration .....................................................................................29  
9.5  Accountability  ......................................................................................................29  
9.6  Concomitant Therapies .......................................................................................30  
9.7  Prohibited Concomitant Therapies ....................................................................30  
9.8  Lifestyle Restrictions ...........................................................................................31  
9.9  Permitted Concomitant Therapies .....................................................................31  
9.10  Compliance ...........................................................................................................31  
9.11  Reporting Product Complaints ...........................................................................31  
10 ADVERSE EVENTS ................................................................................................33  
10.1  AEs of Special Interest.........................................................................................34  
10.2  Assessing and Documenting Adverse Events ....................................................34  
10.3  Time Period for Collecting Adverse Events ......................................................34  
10.4  Assessment of Intensity........................................................................................34  
10.5  Assessment of Causality ......................................................................................35  
10.6  Clinical Laboratory Changes ..............................................................................36  
10.7  SUBLOCADE Depot Removal ...........................................................................36  
11 SERIOUS ADVERSE EVENT ................................................................................37  
11.1  Definition of Serious A dverse Event ..................................................................37  
11.2  Documenting Serious Adverse Events ...............................................................38  
11.2.1  Investigator Reporting of Serious Adverse Events .....................................38  
11.2.2  Regulatory Reporting Requirements for Serious Adverse Events ............39  
12 PREGNANCY ...........................................................................................................39  
12.1  Collecting and Reporting Pregnancy Information ...........................................39  
12.2  Action to be Taken if Pregnancy Occurs in a Female Subject ........................40  
13 DATA MANAGEMENT ..........................................................................................40  
13.1  Data Collection and Management ......................................................................40  
13.2  Database Quality Assurance ...............................................................................40  
13.3  Source Documentation.........................................................................................40  
14  STATISTICS .............................................................................................................41  
14.1  General Procedures .............................................................................................41  
14.2  Sample Size ...........................................................................................................41  
14.3  Analysis Populations ............................................................................................41  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 11 of 52 
 
 
   
   
 14.4  Analysis of Primary, Secondary  and Exploratory Endpoints .........................41 
14.4.1  Primary En dpoint ..........................................................................................41  
14.4.2  Analysis of Other Safety Data .......................................................................42  
14.4.3  Other Safety Variables ..................................................................................42  
14.5  Demographic and Baseline Characteristics .......................................................42  
14.6  Interim Analysis ...................................................................................................42  
15 ETHICS AND RESPO NSIBILITIES .....................................................................43  
15.1  Good Clinical Practice .........................................................................................43  
15.2  Data and Safety Monitoring Committee ............................................................43  
15.3  Institu tional Review Board/Independent Ethics Committee ...........................43  
15.4  Informed C onsent ................................................................................................43  
15.5  Study Files and Record Retention  ......................................................................44  
16 AUDI TING AND MONITORING ..........................................................................44  
17 AMENDM ENTS .......................................................................................................46  
18 STUDY REPORT AND PUBLICATIONS ............................................................47  
19 STUDY DI SCONTINUATION ...............................................................................48  
20 CONFIDENTIALI TY ..............................................................................................49  
21 REFERENCES .........................................................................................................50  
22 APPENDI X 1 .............................................................................................................51  
LIST OF TABLES 
Table 1   Schedule of Assessments – Overview of Study ......................................21  
 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 12 of 52 
 
 
   
   
 LIST OF ABBREVIATIONS 
AE adverse event 
ALT alanine aminotransferase 
BMI body mass index 
CRF case report form 
EOT end of treatment 
GCP Good Clinical Practice 
GMP Good 
Manufacturin g Practice 
ICF informed consent form 
ICH International Council for Harmonisa tion of Technical Requirements for 
Pharmaceuticals for Huma
n Use 
IRB Institutional Review Boar d 
MedDRA Medical Dictionar y for Re gulator y Activities 
mg Milli gram 
MAOI monoamine oxidase inhibito r 
MOUD Medication for Opioid Use disorde r 
NNRTI non-nucleoside reverse transcriptase inhibito r 
NMP N-meth yl-2-p yrrolidone 
OUD opioi d use disorde r 
PLGH pol y(DL-lactide-co- glycolide) with a carbox ylic acid end group 
QA qualit y assurance 
SAE serious adverse event 
SAP statistical anal ysis pla n 
SC subcutaneous(l y) 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 13 of 52 
 
 
   
   
 SD standard deviatio n 
SOP standard operatin g procedure 
SUSA R suspected unexpected serious adverse reactio n 
TEAE treatment-emer gent adverse event 
TM Transmucosal 
UDS urine dru g scree n 
ULN upper limit of normal 
USPI United States Prescribin g Information 
WHO World Health Or ganization 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 14 of 52 
 
 
   
   
 1 INTRODUCTION AND RATIONALE 
1.1 Background 
Opioid use disorder (OUD) is a neurobeha vioral syndrome charac terised by repeated, 
compulsive seeking or use of an opioid desp ite adverse social, psyc hological and physical 
consequences ( SAMHSA 2004 ). This chronic, relapsing disease has grown to epidemic 
proportions. The clinical cour se of OUD typically includes periods of exacerbation and 
remission, but the patient is never dis ease-free. Medications for OUD (MOUD) are 
recomm end
ed by treatment guidelines as the current standard of care for OUD 
(Kamp man 2015), com
bined with counselling/behavi oural therapy to provide a whole-
patient approach to the treatment of OUD.   
SUBLOCADE™ (extended-releas e buprenorphine) injection, fo r subcutaneous (SC) use 
(CIII) is an extended-release formulation of  buprenorphine, a mu-opioid recep
tor partial 
agonist. SUBLOCADE is administered on ce monthly by SC injection and provides 
sustained plasma levels of buprenorphine over the dosing interval. SUBLOCADE uses 
buprenorphine and the ATRIGEL® Delivery System, which cons ists of a biodegradable 
polymer poly (DL-lactide-co-glycolide) w ith a carboxylic acid end group (PLGH), 
dissolved in a biocompatible solvent, N- methyl-2-pyrrolidone (N MP). SUBLOCADE is 
injected as a solution, and subsequent precip itation of the polymer creates a solid depot 
containing buprenorphine. After initial formation of the depot, bupre norphine is released 
via diffusion from, and the bi odegradation of, the depot.  
See SUBLOCADE USPI  for further information.  
1.2 Study Rationale 
Currently, patients who are appropriate can didates for SUBLOCAD E must initiate 
trea
tment with transmucosal (TM) bupre norphine for a minimum of 7 days before 
receiving their first injection 
(SUBLOCADE United States Pres cribing Information [USPI] ).  Study INDV-6000-403 
is being conducted to evaluate the safety and tolerability of starting SUBLOCADE 
treatm
ent following a shorter period of TM buprenorphine treatment. This study (INDV-
6000-404) is to provide ongoing treatment with SUBLOCADE for up to 5 additional 
injections and safety monitoring for subj ects who initiated SUBLOCADE following a 
single dose of transmucosal (TM) buprenorphine in study INDV-6000-403.  
1.2.1 Dosing Regimen 
SUBLOCADE should be administered as per the instructions  for use in the 
SUBLOCADE USPI .  
The recommended initial dose of SUBLOC ADE is 300mg monthly for the first 2 
injections of treatment. Subjects have rece ived 1 x 300mg SUBLOC ADE injection in the 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 15 of 52 
 
 
   
   
 INDV-6000-403 study, therefore subjects must  receive 300mg SUBLOCADE for the 
first injection of this study. Subjects may receive either 100 mg or 300 mg SUBLOCADE 
for the m a
intenance dose (all subsequent injections), based on the medical judgment of 
the Investigator as per the SUBLOCADE USPI .  
1.3 Risk-Benefit Assessment  
Buprenorphine is a partial a gonist at the m u-opioid receptor. As such, it produces a 
submaxim al
 pharmacological response compared  with that of a full agonist at these 
receptors and provides a greater margin of safety with respect to respiratory depression 
compared with full agonists. Buprenorphine ha s been shown to be an efficacious and safe 
treatment for OUD when used as directe d. For this extensi on study, SUBLOCADE will 
be administered as recommended in the SUBLOCADE USPI.  
1.3.1 Risk Assessment  
The safety profile of buprenorphine is well-established, and the AE profile of 
buprenorphine is well characterised. Co mmonly reported treatment-emergent AEs 
include drug withdrawal syndrome, constipation, headache, nausea and vomiting. 
Buprenorphine has been approved for multiple indications and routes of administration 
(e.g., TM, buccal, intramuscular, intravenous, tr ansdermal, rectal and subcutaneous) in 
multiple countries and by various manufacturers. Buprenorphine extended-release SC 
injection was approved as a monthly treatment for OUD in 2017 ( SUBLOCADE USPI ).   
The most common adverse drug reactions with SUBLOCADE were constipation, nausea, 
hepatic enzyme increased, headache, injec
tion site pain, injection site pruritus, vomiting 
and fatigue. Injection site reac tions were generally mild to moderate in severity, none 
were serious, and they decreased in frequency with subsequent inj ections. There were no 
unexpected safety findings. The safety prof ile of SUBLOCADE observed in the Phase III 
studies was generally consiste nt with the known safety prof ile of buprenorphine, with the 
expected exception of injection site tolera bility and reaction.  
1.3.2 Benefit Assessment  
Clear efficacy was demonstrated both in th e pivotal and in additional supporting studies 
of the SUBLOCADE clinical development programme ( SUBLOCADE USPI ). While 
subjects will receive limited benefit fr om participation in the single-dose (of 
SUBLOCADE) study (INDV-6000-403), particip ation in the combined INDV-6000-403 
and INDV-6000-404 studies will allow more meaningful en gagem
ent with MOUD and 
the results could provide support for mo re rapid SUBLOCADE initiation, which is 
expected to improve treatment compliance, e ngagement and retention in treatment.  With 
increasing amounts of fentanyl contaminati on of the heroin drug supply, it is also 
important to treat patients with  a medicine that can protect th em from overdose as soon as 
they are willing to engage in treatment.  Recently reported data ( Wiest 2019 ) supports 
that buprenorphine, administered at doses resu lting in consistent plasma levels of 2ng/mL 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 16 of 52 
 
 
   
   
 and 5ng/mL (similar to the concentrations resulting from both labelled doses of 
SUBLOCADE), is able to dose dependently  inhibit fentanyl-i nduced respiratory 
depression.  Being able to in itiate treatment-seeking pa tients with SUBLOCADE on the 
1st day of treatment ma y therefore help to pr otect patients when they are most vulnerable.
  
1.3.3 Overall Risk-Benefit Summary  
Taken together, these findings indicate a fa vourable benefit/risk assessment for this 
extension of the single dose study (INDV-6000- 403) to evaluate a more rapid treatment 
initiation protocol for SUBLOC ADE in patients with OUD. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 17 of 52 
 
 
   
   
 2 STUDY OBJECTIVE 
The objectiv e of this study is to assess the longer-term safety of an  abbrev iated initia
tion 
protocol of SUBLOCADE in subjects who have completed INDV-6000-403.  It is also to 
provide treatment to these individuals while they seek longer-term care arrangements, as 
it (on average) takes an i ndividual with OUD 6 months be tween seeking treatment and 
achieving an appointment at a provider within the US.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 18 of 52 
 
 
   
   
 3 STUDY ENDPOINTS  
3.1 Primary 
The proportion of subjects with treatment emer gent adverse events (TEAEs) at any time 
during the treatme nt period (i.e., any tim
e after administration of SUBLOCADE).  
3.2 Other Safety Assessments 
Additional safety endpoints will include assessment of: drug-related TEAEs, serious 
TEAEs, drug-related serious TEAEs, TEAEs leading to treatment discontinuation and 
concomitant medications. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 19 of 52 
 
 
   
   
 4 STUDY PLAN 
4.1 Study Design 
 
This is a single center, open-label, S UBL OCADE treatment extens ion study in which up 
to 25 subjects diagnosed with moderate or  severe OUD will be en rolled. A subject is 
defined as enrolled when the first dose of SUBLOCADE is administer ed for this study.  
Only subjects who have com pleted the End of Treatm
ent (EOT) procedures for Study 
INDV-6000-403, have signed the INDV-6000-404 in formed consent form (ICF), and 
meet all the enrollment criteria may be considered for inclus ion in this study.  
The INDV-6000-403 EOT visit is 28 days afte r the subjects first dose of SUBLOCADE 
in INDV-6000-403, therefore the INDV-6000-403 EOT and the INDV-6000-404 
screening and Day 1 visit for this study will occur within 2 days.  
The ICF may be shared with the potentia l subject before the INDV-6000-403 EOT Visit 
to discuss this study as a possi ble treatment option. However, the ICF must not be signed 
until all assessments for the I NDV-6000-403 EOT Visit are complete. 
 
The INDV-6000-403 EOT assessments will serve as the screening assessments for the 
Screening Visit (Day 1) of this study. A ny AEs and concomitant medications ongoing at 
the INDV-6000-403 EOT will be re-recorded fo r this study. In addition, demographics, 
height, medical/psychiatric, substance and drug of abuse history will not be re-collected 
and will be taken from the INDV-6000-403 scr eening assessments. A detailed detox and 
MOUD treatment history will be collected at  screening. For those subjects who have 
enrolled in the study prior to approval of  protocol amendment 1, their detox and MOUD 
treatment history will be collected re trospectively at th eir next visit. 
 
On Day 1, eligible subjects will receive a SC injection of 300mg SUBLOCADE.  
Before departing the site, any new adverse events (AEs) or concomitant medications will 
be recorded. 
 
Subjects will return to the site for monthly injection visits every 4 weeks (-2 / +7 days) 
for a total of up to 5 injecti ons. At Injection Visits 2 thr ough 5, subjects will be evaluated 
in accordance with local standard of care and results for the following procedures will be 
recorded: urine pregnancy test (to be perf ormed before SUBLOCADE administration for 
all female subjects who are of childbeari ng potential); urine dr ug screen (UDS) and 
evaluation of previous injection site for pot ential reaction and evidence of attempts to 
remove the depot. For injections 2 to 5, s ubjects may receive e ither a dose of 100 mg 
SUBLOCADE or 300 mg SUBLOCADE, base d on the medical judgment of the 
Investigator, per the SUBLOCADE USPI . During each visit the subject will be assessed 
for AEs and use of concomitant medications.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Pa ge 20 of 52 
 
 
   
   
 All subjects will receive couns elling as determined by local standard of care throughout 
the study from Day 1 through EOT. 
All subjects who receive SUBL OCADE (including those who wi sh to discontinue early), 
will be enco uraged to attend the EO T/ET visit 4 weeks af
ter SUBLOCADE 
administration.  
At the EOT/ET Visit, results for the following procedures and assessments will be 
recorded:  urine pregnancy test for all fema le subjects who are of childbearing potential; 
evaluation of previous injection site for pot ential reaction and evidence of attempts to 
remove the depot; UDS; use of concomitant medications and assessment for AEs. At 
every Visit options for continued care should be discussed with the subject. 
Any subject with ongoing AEs or concomitant me dications at the EOT Visit will also be 
followed up by telephone 4 weeks later for a safety follow up to assess the ongoing AEs 
or concomitant medications only. 
4.2 Schedule of Assessments 
An overview of the schedule of asse ssments for the study is provided in Table 1 . 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (exte
nded-release buprenorphine) Page 22 of 52 
 
  
  
 3. This data will n o
t be re-collected; the data from the INDV-6000-403 EO T visit will be used.  
4. Any ongoing (at the INDV-6000-403 EOT) or new AEs or concomitant medications in this study will be recorded.  
5. Required for female subjects of childbearing potential only, to be performed before SUBLOCADE dosing at Visits 1 to 6.  
6. Qualitative test to be performed before  SUBLOCADE dosing at Visits 1 to 6.  
7. Injection site will be evaluated for signs of attempted removal before SUBLOCADE dosing at Visits 1 to 6. Any injection site  reactions or infections will be 
recorded as AEs. 
8. All subjects will receive counselling as determined by local standard of care throughout the study from Day 1 through EOT. 
9. All subjects who receive SUBLOCADE (includi ng those who wish to discontinue early), will be encouraged to attend the EOT vis it 4 weeks after 
SUBLOCADE administration.  
10.  Any subject with ongoing AEs or concomitant medications at  the EOT/ET Visit will also be followed up by telephone 4 weeks later for a safety follow up to 
assess the ongoing AEs or concomitant medications only.  
11. A detailed detox and MOUD treatment history will be collected at screening. For those subjects who have enrolled in the stu dy prior to approval of protocol 
amendment 1, their detox and MOUD treatment history will be collected retrospectively at their next visit. 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 23 of 52 
 
  
  
 5 POPULATION 
5.1 Number of Subjects 
Up to 25 adult subjects with moderate or  severe OUD who are s eeking MOUD and have 
completed the EOT Visit for the INDV-6000-403 study are planned to be enrolled into 
the study.  
5.2 Inclusion Criter ia
 
Subjects must meet all the following criteria to be eligible for the study:  
1. Signed the informed consent form (ICF) a nd have the ability to comply with the 
requirements and restrict ions listed therein.  
2. Completed the EOT Visit for the INDV-6000-403 Study.  
3. Is an appropriate candidate in the opinion of the Investigator or medically qualified 
sub-Investigator. 
5.3 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from the study: 
1. Subject compliance issues during part icipation in the INDV-6000-403 study which, 
in the opinion of the Investigator, coul d potentially compromi se subject safety. 
2. Subjects who are unable, in the opinion of the Investigator or Indivior, to comply 
fully with the study requirements including those who are currently incarcerated or 
pending incarceration/legal action. 
5.4 Subject Screening 
Subjects who provide written informed  consent will have their INDV-6000-403 
assessments (per Table 1 ) re-reviewed to conf irm study eligibility. 
5.5 Deviation from Inclus ion/Exclusion Criteria 
Waivers fro m inclusion and exclusion criter ia are not allowed because they have the 
potential to jeopardise subject safety, the scientific integr ity of the study or regulatory 
acceptability of the data. Indivior  does not gran t waivers to the protoco
l-defined inclusion 
and exclusion criteria, and strict adherence to these criteria as outlined in the protocol is 
essential. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 24 of 52 
 
  
  
 6 STUDY CONDUCT 
6.1 Subject Screening 
Study screening begins once written informed  consent is obtained ; the same subject 
identification number from INDV-6000-403 will  be assigned. The subject identification 
numb
er will be used to identify the subject  during the screening process and throughout 
study participation, if applicable.  
The Investigator is responsible for maintaini ng a master list (i.e., a subject identification 
list) of all consented subj ects and will document all subjects that do not meet study 
eligibility criteria (i.e., screen failures), incl uding reason(s) for inelig ibility (i.e., a subject 
screening and enrolment log). This document will be reviewed by Indivior or designated 
representative for accuracy and completeness.  Ineligible subjects, as defined by the 
protocol-specific inclusion and exclusion criteria, should not re ceive study drug and 
should be documented as screen failures.   
6.2 Enrolled 
A subject will be considered enrolled if he/s he receives at least 1 dose of SUBLOCADE. 
6.3 Not Enrolled 
A subject will be considered not enrolled if written informed consent is obtained but the 
subject does not receive SUBLOCADE. Reasons for not enrolling (e.g., withdrawal of 
consent, does/not meet specified inclusion or exclusion criteria) will be recorded in the 
case report form (CRF).  
6.4 Treatment Period 
Treatment period begins when the SUBLOCADE  injection is given on Day 1 and ends 
after all assessments have been  made at the EOT Visit.  
6.5 Treatment Period Completion  
A subject will be considered as completing the treatment period if they have received 
Injection 1 and Injection 5.   
6.6 Study Completion  
A subject will be considered to have complete d the study if they have completed the last 
injection visit (Injection 5) and the scheduled EOT visit.   
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 25 of 52 
 
  
  
 6.7 Early Termination  
A subject will be considered an Early Termin ation if he/she is dosed with SUBLOCADE 
and does not complete the study (did not comple te the last injection visit [Injection 5]) 
and the scheduled EOT visit.  
Reasons for early termination (e.g., withdr awal of consent, lost to follow up, 
identif i
cation / move to alternative treatment site) will be recorded in the CRF. Subjects 
who Early Terminate from the study will be encouraged to attend the ET visit 4 weeks 
after SUBLOCADE administration, as well as  a safety follow up via telephone if any 
AEs and concomitant medications are ongoing at the time of the ET visit.  
6.8 Withdrawal and Stopping Criteria   
6.8.1 Subject Withdrawal from the Study  
If the subject has discontinued study treatmen t (including depot removal) and is no longer 
being followed for study assessments and procedures (including follow-up procedures), 
he/she will be considered withdrawn from the study. The primary reason for withdrawing 
from the study must be entered into the CRF  (e.g., subject is lost to follow-up, Indivior 
terminates the study or Inve stigator’s discretion).   
6.8.2 Subject Withdrawal of Consent  
If a subject withdraws consent, the subject will not rece ive any additional doses of study 
drug. However, the subject may be offered add itional tests as needed to monitor safety 
(e.g., EOT safety assessments or procedures).  
6.8.3 Subjects Lost to Follow-up  
In cases of a missed visit, the Investigator or designee must attempt to contact the subject 
and re-schedule as soon as possible. The I nvestigator or designee must counsel the 
subject on the importance of maintaining the assigned visit schedule and ascertain 
whether or not the subject wishes to and/or should conti nue in the study.   
In the event a subject is lost to follow-up, the Investigator or designee must make a 
reasonable effort to contact the subject. Tw o documented attempts (e.g., telephone, email, 
etc.) to contact the subject fo llowed by a certified mailed letter is considered reasonable.  
For the purpose of documenting date of discont inuation for a subject confirmed to be lost 
to follow-up, the date of discontinuation should be the date of la st contact with the 
subject.   
In the case where a certified letter is sent but not confirmed as received by the subject, the 
date of discontinuation is the date  the certified letter was sent.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 26 of 52 
 
  
  
 In the case where a certified letter is sent  and has been confirme d as received by the 
subject, the date of discon tinuation is the date of the confirm
ed subject receipt.  
In the event that neither of these above cases applies (which  should be explained in the 
source documents), the date of discontinuation is the date of the subject's last study visit.  
7 STUDY SUSPENSION OR TERMINATION 
Indivior reserves the right to temporarily suspend and/or perman ently discontinue the 
study at any time and for any r eason, including safety or ethi cal concerns or severe non-
compliance. If such action is taken, Indivior  will discuss the rationale for the decision 
with the Investigator. In cases where a st udy is suspended or terminated for safety 
reasons, Indivior will promp tly inform Investigators and the Regulatory Authorities of 
this action and the reason(s) for th e suspension or termination.   
If required by applicable regulations, the I nvestigator must inform the Institutional 
Review Board (IRB) promptly and provide  the reason(s) for the suspension or 
termination. If the study is prematurely discontinued, all study data and study drug 
remaining at the clinic must be returned to Indivior or its design ated representative.  
8 DESCRIPTION OF ST UDY PROCEDURES 
Study subjects will be evaluated in accordan ce with local standa rd of care, and only 
results for study specific assessments and proced ures will be recorded in the CRF. Study 
assessments and procedures, including the timing of assessments, are summarised in 
Table 1 . Further details on safety asse ssments are provided in Section 8.2.  
A signed written ICF must be obtained from the subject before any study assessments or 
procedures m a
y be performed. All assessments  and procedures may be performed more 
frequently, if clinically indicated.  
8.1 Demographics and Medical/Psychiatric History 
A detailed medical and psychiatric hi story was collected during the INDV-6000-403 
study and will not be re-collected. A detailed  detox and MOUD treatment history will be 
collected at screening. For those subjects who have enrolled in the study prior to approval 
of protocol amendment 1, their detox and MOUD treatment history will be collected 
retrospectively at their next visit. 
8.2 Safety Assessments 
Definitions and procedures for reporting AEs and SAEs are provided in Sections 10 and 
11, respectively. 
8.2.1 Clinical Laboratory Tests  
Clinical laboratory tests for Virology, Haematology, Serum Chemistry and Urinalysis 
were collected during the INDV-6000-403 study and will not be re-collected.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 27 of 52 
 
  
  
 8.2.1.1 Urine Drug Screening (UDS) 
A qualitative UDS will be conducted at each Vis it, as per the schedule of events in 
Table 1 . The UDS will in clude th
e following substances:  
 Opioids 
 Oxycodone  
 Morphine 
 Fentanyl 
 Methadone 
 Cocaine 
 Ampheta
mines 
 Cannabinoids 
 Barbiturates 
 Benzodiazepines 
 Methamphetamine 
 Phencyclidine 
Additional information related to the colle ction and handling of urine specimens is 
located in the laboratory manual.  
8.2.1.2 Urine Pregnancy Test 
A urine pregnancy test will be performed at each  visit using a licensed test (dipstick), for 
females of child bearing potential only.  
Additional information related to the colle ction and handling of urine specimens is 
located in the laboratory manual.  
8.2.2 Injection site Evaluation  
The Injection site will be evaluated for signs  of attempted removal before dosing with 
SUBLOCADE at each visit, as shown in Table 1 . Any attempts at a SUBLOCADE depot 
removals by the subject should be reported as an AE, and any removals should be 
reported as an AE of Special Interest, see Section 10.7. Any injection site reactions or 
inf
ections will be recorded as AEs. 
8.3 Protocol Deviations 
A protocol deviation is any non-compliance with the clinical  study protocol or ICH/GCP 
requirements. The non-compliance may be on the pa rt of the subject, the Investigator or 
the study clinic staff. As a result of deviati ons, corrective actions ar e to be developed by 
the clinic and implemented promptly a nd in accordance with ICH E6. It is the 
responsibility of the Investig ator and study clinic staff to  use continuous vigilance to 
identify and report deviations to Indivior or specified designe e and the IRB. All 
deviations must be reported in the study source documents. Pr otocol deviations must be 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 28 of 52 
 
  
  
 sent to the IRB as required. The Investigator  and study clinic staff are responsible for 
knowing and adhering to th e IRB’s requirements. 
9 STUDY DRUG MANAGEMENT 
The study drug, SUBLOCADE, will be provided by the Sponsor in two strengths 100 mg 
and 300m
g buprenorphine.  
9.1 Description 
9.1.1 Formulation  
SUBLOCADE is a colourless to amber steril e solution for SC injection designed to 
deliver a buprenorphine dose at a controlled rate over a 1-month period. The active 
ingredient in SUBLOCADE is buprenorphine (free base), a mu-opioid receptor partial 
agonist and a kappa-opioid re ceptor antagonist. Buprenorphi ne is dissolved in the 
ATRIGEL delivery system at 18% by wei ght and is a biodegradable 50:50 poly (DL-
lactide-co-glycolide) polymer and a biocom patible solvent, N-methyl-2-pyrrolidone.  
Adequate precautions must be taken to avoid direct contact with the study drug. 
Occupational hazards and recommended handling procedures are provided in the Safety 
Data Sheet.  
9.1.2 Storage 
SUBLOCADE must be stored in a refriger ator at 2° to 8°C (35.6° to 46.4°F) in 
accordance with the USPI, in a secure loca tion with limited access. Once outside the 
refrigerator, SUBLOCADE may be stored in its unopened or iginal packaging at room 
temperature, 15°C to 30°C (59°F to 86°F), for up to 7 days prior to administration. 
Discard SUBLOCADE if left at room temperature for longer than 7 days. 
Temperature excursions outside of the defi ned ranges should be reported to the Sponsor, 
the product should be immediately quarantined and only used if/after Sponsor approval 
has been obtained (see Pharmacy Manual).  
The study drugs must be handled strictly  in accordance with the protocol, USPI, 
Pharmacy Manual and applicable  local laws and regulations. 
9.2 Packaging and Labelling 
The SUBLOCADE clinical study labels will  be developed in accordance with Good 
Manufacturing Practice (GMP) and local regul atory requirements. Detailed information 
regarding the commercial packaging of SUBLOCADE is outlined in the USPI.  
SUBLOCADE inner packaging (pouch) must remain with the outer product carton until 
the time of administration.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 29 of 52 
 
  
  
 9.3 Shipment 
SUBLOCADE will be shipped under monitored re frigerated temperatures between 2ºC to 
8ºC (35.6°F to 46.4°F).  
9.4 Dose and Administration 
SUBLOCADE will be supplied by the Sponsor as  a sing le, pre-filled sy
ringe, the entire 
contents of which should be administered  during a single SC in jection by a licensed 
healthcare provider as delega ted by the Investigator.  
SUBLOCADE should be administered as per the instructions  for use in the 
SUBLOCADE USPI . The recommended initial dose of  SUBLOCADE is 300mg monthly 
for the fi rst 2 injec
tions of treatment. S ubjects have received 1 x 300mg SUBLOCADE 
injection in the INDV-6000-403 study, ther efore subjects must receive 300mg 
SUBLOCADE for the first injection of this study.  
Subjects may receive either 100 mg or 300 mg SUBLOCADE for the maintenance dose 
(all subsequent injections), based on the medi cal judgment of the Inve stigator as per the 
SUBLOCADE USPI . Reasons for dose adjustments shoul d be recorded in the source and 
CRF.  
Time of dose for SUBLOCADE is defined as the time the SC injection is complete. The 
time of dose
 and any dosing observations (e.g., partial doses or othe r issues with the 
injection) will be recorded in the source doc umentation; in addition, time of dose will be 
recorded in the CRF.  
The Investigator will not supply SUBLOCAD E to any person except study personnel for 
SC injection of subjects in this study.  SUBLOCADE will be dispensed under the 
supervision of the Investigator, a suitably qualified member of the study team, or by a 
pharmacist. The Investigator or designee ag rees to neither administer SUBLOCADE 
from, nor store it at any location other than the study clinic agreed upon with the Sponsor. 
Clinic personnel must maintain accountabi lity records per the Pharmacy Manual.  
9.5 Accountability 
The Investigator is responsibl e for ensuring that all study drug  received at the clinic is 
inventoried, accounted for and documented in accurate accountability records.  
Accountability records will be  provided to Indivior. All unused study drug will be 
destroyed by the Investigator, as per local  standard operating procedures (SOP). The 
study drug must be handled strictly in accord ance with the protocol, handling guidelines 
and the USPI; it must be stored in a locked, limited-access area under appropriate 
environmental conditions.   
The dispensing of study drug to the subject must be documented on the drug dispensing 
form. All study drug dispensation will be pe rformed by a pharmacist or designee, 
checked by a study centre staff member and documented on a drug dispensation form.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 30 of 52 
 
  
  
 Unused study drug must be available for verification by the monitor during on-site 
monitoring visits.   
9.6 Concomitant Therapies 
Concomitant medication s will be collected f
rom screening (including ongoing 
concomitant medications recorded at  the INDV-6000-403 EOT)  until the INDV-6000-
404 EOT at the time points listed in Table 1 . Any subject with ongoing concomitant 
medications at the INDV-6000-404 EOT will be followed up by telephone 4 weeks later 
for a safety follow up to assess th e ongoing concomitant m e
dications.  
Any concomitant medications (including herbal  preparations) taken during the study will 
be recorded in the source documents and in the CRF. Any changes in concomitant 
therapy during the study will be documented, in cluding cessation of therapy, initiation of 
therapy and dose changes. 
9.7 Prohibited Concomitant Therapies 
Subjects should be instructed not to take  any medications, including over-the-counter 
products, without first discussi ng with the Investigator.   
Supplemental TM buprenorphine (after SUBL OCADE injection) may only be permitted 
after discussions with the medical monitor.   
Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other 
CNS depressants, including alcohol, increases the risk  of respiratory depression, 
profound sedation, coma and death.  
The SUBLOCADE USPI should be referenced regarding use of the below concomitant 
therapies.  
benzodiazepines and other CNS depressants 
cytochrome P450 3A4 inhib itors or inducers (see Appendix 1) 
antiretrovirals: non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
antiretrovirals: prot ease inhibitors 
serotonergic drugs 
monoamine oxidase inhibitors (MAOIs) 
muscle re
laxants 
diuretics 
anticholinergic drugs 
The Indivior medical monitor should be no tified if a subject r eceives any of these 
treatments during the study. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 31 of 52 
 
  
  
 9.8 Lifestyle Restrictions 
Eligible subjects will be advi sed to abstain from alcohol  throughout the study, as central 
nervous system depressants increase the risk  of respiratory depression, profound sedation, 
coma and death in patient s taking buprenorphine ( SUBLOCADE USPI ). 
9.9 Permitted Concomita
nt Therapies 
The Investigator may prescribe concomitant medication s or treatm
ents deemed necessary 
to the subject, except those medications defined in Section 9.7 of this protocol. 
If the subject experiences withdrawal symp toms at any time, he/she may be treated 
symptomatically ( SAMHSA TIP 63 2018 ): 
Nausea: ondansetron or me
toclopramide 
Diarrhoea: loperamide 
Anxiety, irritability, sweating: clon
idine 
Insomnia: diphenhydramine, trazodone 
Pain: nonsteroidal anti-inflammatory drugs 
Supplemental buprenorphine may only be perm itted after discussions  with the medical 
monitor. Subjects will not be discontinued fr om treatment due to illicit opioid use 
(including buprenorphine). 
9.10 Compliance 
All study drugs will be administered in th e clinic and documented in the source and 
recorded in the CRF.  
SUBLOCADE compliance will be assessed by insp ecting the injection site for evidence 
of attempted removal of the depot by the s ubject, documented in the source and recorded 
in the CRF. Likewise, surgical removal by a physician will be documented in the source 
and recorded in the CRF. See Section 10.7 for details on reporting depot removal. 
Use of
 prohibited concomitant medications will be evaluated per the Concomitant 
Medication assessment outlined in the Table 1 , documented in the source and recorded in 
the CRF. 
9.11 Reporting Product Complaints  
The Investigator and study clinic staff are responsible for prompt recognition and 
reporting of product quality complaints to In divior. A product complaint is any concern 
pertaining to the manufacturing or quality cont rol of the study drug and includes, but is 
not limited to, e.g., short counts/empty pouche
s, leaking syringes, broken needles, 
labelling defects, missing inserts, packagi ng defects or difficult to open packaging, study 
drug that is thought to be ineffective, or ha s an appearance or odour that is outside of 
what is expected.   
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 32 of 52 
 
  
  
 All product complaints should be reported to Indivior in a timely manner and the 
following information provided:  
 study number 
 site contact/reported by  

 subject number (if already assigned to a subject)  
 description of issue  
 picture, if available (photographs should be taken only if safe to do so/within site 
policy or practice to take photograph)  
If the product has not yet b een opened (i.e., product does no t pose any hazard), retain the 
product and packaging in a quarantined space until further instruction is provided by 
Indivior. If the product is potentially hazardous , dispose per site process and document in 
the source. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 33 of 52 
 
  
  
 10 ADVERSE EVENTS 
The Investigator or designee is responsibl e for identifying, docume nting and reporting 
events that meet the definition of an AE.    
An AE is any untoward medical occurrence in a subject associated w ith the use of a study 
drug regardless of the presence of a causal relationship to th e study drug. An AE can be 
any unfavourable and unintended sign (i ncluding an abnormal laboratory fi nding) 
sym
ptom or disease (new or exacerbated) temporally associated with a study drug, 
whether or not considered related to the study drug.  
 Events meeting the defin ition of an AE include:  
 New condition detected after study drug administration even though the AE may 
have been present prior to receiving study drug.  
 Exacerbation of a pre-existing condition (i ncluding intensification of a condition 
and/or an increase in frequency).  
 Any abnormal laboratory test  results or other safety  assessments felt to be 
clinically significant in the opinion of the Investigator (including those that 
worsen from baseline).   
 Symptoms and/or the clini cal sequelae of a suspected interaction or an overdose 
of either study drug or a concomitant medication.  
 Signs, symptoms or the clinical sequelae re sulting from special interest conditions 
(e.g., medication error, SUBLOCAD E depot removal, etc.).  
 Symptoms and/or clinical sequelae resulti ng from lack of efficacy will be reported 
if they fulfil the de finition of an AE.  
 Symptoms and/or clinical sequelae that resulted in intervention.  
 Evidence of a subject attempting re moval of the SUBLOCADE depot  
Events that do not meet the de finition of an AE include:  
 Medical or surgical procedures; the condition that leads to the pr ocedure is an AE.  
 Situations where an untoward medical occurrence did not occur (e.g., social 
and/or convenience admission to a hospita l, hospitalisation for elective surgery, 
hospitalisation for observation in  the absence of an AE).  
 Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 34 of 52 
 
  
  
 10.1 AEs of Special Interest 
In this study, an AE of special interest  is any occurrence of a SUBLOCADE depot 
removal (see Section 10.7); Subjects with alanin e aminotransferase (AL T
) ≥3 × upper 
limit of normal (ULN) and bilirubin ≥2 × ULN (> 35% direct) are defined as SAEs of 
special  in
terest.  
This AE of special interest should be re ported to Indivior, by the Investigator (or 
designee) within 24 hours  from first being aware of the event, using the same reporting 
process as for SAEs, see Section 11.2. 
10.2 Assessing and Documenting Adverse Events 
The Investigator is ultimatel y responsible for assessing and reporting all AEs as outlined 
in the protocol. The assessment and reporting of AEs may be delega ted to a m
edically 
qualified sub-Investigator, trained on this st udy protocol, who is listed on the delegation 
of authority log. All AEs regardless of susp ected causal relationshi p to the study drug 
will be reported as described in this protocol.  
Adverse events should be volunteered by the subj ect or solicited from the subject using a 
standard statement, obtained from examination of the subject at a clinic visit, or from 
observations of clinically significant laboratory values or special examination abnormal 
values.  
All AEs are to be assessed and recorded in a timely manner and followed to resolution or 
until the Investigator determines that there is not an anticipated resolution. Each AE is to 
be documented with reference to severity, date of occurrence, duration, treatment and 
outcome. Furthermore, each AE is to be clas sified as being serious or non-serious. In 
addition, the Investigator must assess whet her the AE is study drug-related or not. 
10.3 Time Period for Collecting Adverse Events 
Adverse events will be collected from the time of signed informed consent (including 
ongoing AEs at the INDV-6000-403 EOT) until comp letion of the EOT vi sit. Any subject 
with ongoing AEs at the INDV-6000-404 EOT will be followed up by telephone 4 weeks 
later for a safety follow up to assess the ongoing AEs. 
Subjects with ongoing SAEs at the safety fo llow up telephone contact that, in the opinion 
of the Investigator, are associated with the study drug, will be followed and reported as 
described in Section 11. Subjects with ongoing AEs at sa fety follow up telephone contact 
that, in the o
pinion of the Investigator, are associated with the study drug, will be 
followed and reported as described in Section 10.2. 
10.4 Assessment of Intensity 
The term “severe” is used to describe the in tensity (severity) of a specific event (as in 
mild, moderate, or severe); the event itself, however, ma
y be of relatively minor medical 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 35 of 52 
 
  
  
 significance (such as a severe headache). This  is not the same as “serious”, which is 
based on subject/event outcome or  action criteria usually associated with  events that pose 
a threat to a subject’ s life or functioning. Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations. 
 
Intensi
ty  Definition  
Mild  Causes transient or mild discomfor t; no limitation of us ual activities; no medical 
intervention required  
Moderate  Causes mild to moderate limitation in activity; some limitation of usual activities; no 
or minimal me
dical intervention or therapy is required  
Severe  Causes marked limitation in activity; some assistance is usually required; medical 
intervention or therap
y is required ; hospitalisation is probable    
Adverse events with changes in severity should be documented as separate events. 
10.5 Assessment of Causality 
The Investigator or a medically qualified sub -Investigator, trained on this study protocol, 
listed on the delegation of authority log is responsible for determining the AE 
relationship to the study drug.  
The following categor
ies will be used to define the relationship of an AE to the 
administration of the study drug:  
Not Related: Data are available to identify a clear alternative cause for the AE other 
than the study drug.  
 Related:  The cause of the AE is rela ted to the study drug an d cannot be reasonably 
explained by other factors (e.g., the s ubject’s clinical st ate, concomitant 
therapy and/or other interventions).  
A “reasonable possibility” is meant to convey that there are facts/evidence or arguments 
to suggest a causal relationship, rather than that a relations hip cannot be ruled out. The 
Investigator will use clinical judgment to de termine the relationshi p. Alternative causes, 
such as natural history of the underlying diseases, concomitant therapy, other risk factors 
and the temporal relationship of the even t to the study drug will be considered and 
investigated. The Investigator will also consu lt the USPI in the determination of his/her 
assessment. For each AE/SAE, the Investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and ha s provided an assessment of causality.  
There may be situations when an SAE or AE  of special interest has occurred, and the 
Investigator has minimal information to incl ude in the initial report to Indivior or 
designated representative. However, it is impera tive that the Investigator always make an 
assessment of causality for ever y event prior to the initial transmission of the SAE or AE 
of special interest data to Indivior or designated represen tative. The Investigator may 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 36 of 52 
 
  
  
 change his/her opinion of causality in light of follow-up information and amend the SAE 
or AE of special interest da ta collection tool accordingly. The causality assessment is one 
of the criteria used when determin ing regulatory reporting requirements. 
10.6 Clinical Laboratory Changes 
Clinical Laboratories are not  collected for this study. However, if an Investigator 
performs these tests as part of the local sta ndard of care the results m a
y be considered a 
reportable AE only if the lab test result is associated with accompanying symptoms, and/ 
or requires additional diagnostic  testing or intervention (medical, surgical), and/or 
requires additional significant treatment, and/or requires temporal or permanent 
discontinuation of study drug, or a change to dos ing other than as permitted by protocol.   
If a subject experiences any of  the below Liver Chemistry cr iteria the Indivior medical 
monitor should be notified to discuss the subject’s course of action: 
1. The subject has ALT >3 × ULN and bilirubin >2 × ULN ( ˃35% direct bilirubin). 
2. The subject has ALT >3 × ULN and a ssociated with symptoms (new or 
worsening) believed to be related to he patitis (such as fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, or  jaundice) or hypersensitivity (such as 
fever, rash or eosinophilia). 
3. The subject has ALT >5 × ULN but <8  × ULN persisting for >2 weeks. 
4. The subject has ALT >5 × ULN but <8 × ULN and cannot be monitored weekly 
for ≥2 weeks.  
5. The subject has ALT >8 × ULN. 
If the subject experiences Criterion 1, this is an SAE (important medical event) of special 
interest, that must be reported  to Indivior as per Section 11.2.1 .  
10.7 SUBLOCADE Depot Removal 
If clinically indicated, the SUBLOCADE de pot may be surgically removed within 
14 days of injection. Any occurrence of depot removal will be  captu
red in the database as 
an AE of special interest. In addition, the AE  that resulted in the depot removal needs to 
be reported; this is not an AE of special  interest. Additional de tails about the depot 
removal (e.g., whether the depot was removed by the subject or the Investigator and 
whether this was voluntary or  involuntary [i.e., whether the subject agreed to the 
removal]) also need to be reported. Depot removal should be reported using the same 
timing as for SAEs (see Section  11.2.1 ). 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 37 of 52 
 
  
  
 11 SERIOUS ADVERSE EVENT 
11.1 Definition of Serious Adverse Event 
The Investigator or designee is responsibl e for identifying, docume nting and reporting 
events that meet the definition of an SAE. 
An SAE is any event that meets any of the following criteria: 
Death 
Life-threatening 
Inpatient hospitalisation or prolongation of existing hospitalisation 
Persistent o r
 significant disability/incapacity 
Congenital anomaly/birth defect in the offs pring of a subject who received study drug 
Other: Important medical events that may not result in death, be life-threatening or 
require hospitalisation, may be consider ed an SAE when, based upon appropriate 
medical judgment, they may jeopardise th e subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such events are: 
○ intensive treatment in an emergency room or at home for allergic bronchospasm 
○ blood dyscrasias or convulsions that do not  result in inpatient hospitalisation 
Subjects with ALT ≥3 × ULN and bilirubin ≥2 × ULN (> 35% direct) are defined as 
SAEs of special interest (important medical event). 
An AE is considered “life-thr eatening” if the subject was at  immediate risk of death from 
the event as it occurred; i.e., it does not include  a reaction that if it had occurred in a more 
serious form might have caused death. For example, study drug-induced hepatitis that 
resolved without evidence of hepatic failure would not be considered life-threatening 
even though study drug-induced hepatitis can be fatal.  
The AEs requiring hospitalisation should be  considered SAEs. Hospitalisation for 
elective surgery or rou tine clinical procedures that are not the result of AE (e.g., elective 
surgery for a pre-existing condition that has not worsened) should not be considered AEs 
or SAEs. If anything untoward is reported dur ing the procedure, that occurrence must be 
reported as an AE (either “serious” or “non-serious”) according to the usual criteria.  
In general, hospitalisation signifies that the subject has been detained (usually involving 
at least an overnight stay) at the hospita l or emergency ward for observation and/or 
treatment that would not have been appropr iate in the physician’s office or other 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 38 of 52 
 
  
  
 outpatient setting. Complications that occu r during hospitalisation are AEs. If a 
complication prolongs hospitalisa tion or fulfils any other seri ous criteria, the event is 
serious. When in doubt as to whether “hospita lisation” occurred or was necessary, the AE 
should be considered serious.  
An AE is incapacitating or di sabling if the experience resu lts in a substantial and/or 
perm
anent disruption of the subject’s ability to carry out normal life functions. 
11.2 Documenting Serious Adverse Events 
When an SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g., hospital progress notes, labo ratory and diagnostic reports) pertaining 
to the event. The Investigator will then reco rd all relevant information regarding an SAE 
on the appropriate electronic or paper form(s).  
It is not acceptable for the Investigator to send photocopi es of the subject’s medical 
records to Indivior in lieu of completi on of the SAE Reporting Form. However, there 
may be cases where copies of medical record s are requested by Indivior or designated 
representative. In this instance, all subject  identifiers, with the exception of subject 
number, will be redacted on the copies of the medical records prior to submission to 
Indivior.  
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical informa tion. In such cases, the diagnosis will be 
documented as an AE or SAE and no t the individual signs/symptoms. 
11.2.1 Investigator Reporting of Serious Adverse Events  
Once the Investigator determines that an even t meets the protocol definition of an SAE, 
the SAE will be reported to Indivior (or desi gnated representative) by the Investigator (or 
designee) within 24 hours  from first being aware of the event. Any follow-up 
information on a previously reported SAE will also be reported to Indivior within 
24 hours.  
Where additional information is needed or e xpected, the Investigat or will not wait to 
receive all information before reporting the event to Indivior. The Investigator must 
provide an assessment of causality at the ti me of the initial report as described in 
Section 10.5 of the protocol.   
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 39 of 52 
 
  
  
 In the event of an SAE, the Investigator or  designee will notif y Indivio
r Global Safety by 
completing the paper SAE Reporting Form a nd submitting the form to Indivior Global 
Safety via email or fax: 
Email: PatientSafetyNA@indivior.com    
Fax: (804) 423-8951 
11.2.2 Regulatory Reporting Requirements  for Serious Adverse Events  
Prompt receipt of notifications of SAEs to Indivior or designated repres entative from 
Investigators is essential in ensuring that legal obligations and et hical responsibilities 
regarding the safety of  subjects are m
et.  
Indivior has a legal responsibi lity to notify both the local regulatory authority and other 
regulatory agencies about the safety of  a study drug.  Indivior or designated 
representative will comply with country-sp ecific regulatory requirements pertaining to 
safety reporting to Regulatory Author ities, IRBs and Investigators.  
A suspected unexpected serious adverse reaction (SUSAR) is an  SAE related to the study 
drug administered in any dose and that, in its nature or severity, is inconsistent USPI. 
Indivior Global Safety will determine if an SAE meets the definition of a SUSAR and 
distribute SUSAR reports according to local regu latory requirements and Indivior policy. 
An Investigator who receives the safety report  describing an SAE or other specific safety 
information (e.g., summary or line listing of SAEs, Dear Investigator  Letter) will file it 
with the USPI and will notify the IRB, if required according to local requirements.   
12 PREGNANCY  
12.1 Collecting and Reporting Pregnancy Information  
Information on all pregnancies will be collected from receipt of study drug until 12 
months following the last dose of SUBLOCADE  (approximately 5 terminal half-lives). 
All confirmed pregnancies that occur within  this study will be followed until resolution 
(i.e., termination [voluntary or  spontaneous] or birth).   
Pregnancy of a study subject wi thout associated unexpected or adverse sequelae is not a 
reportable AE but must be reported to Indivior Global Safety (or designated 
representative) using the Clinical Trial Pr egnancy Tracking Form within 24 hours of the 
Investigator or designee firs t being aware of the pregnanc y (contact details for reporting 
via email or fax are the same as for SAEs).  
The pregnancy must be followed up to determine outcome (including premature 
termination) and status of mother and infant. Generally, follow-up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of foetal status (presence or absence of anomalies) 
or indication for procedure.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 40 of 52 
 
  
  
 Any pregnancy complication or elective terminat ion for medical reasons must be reported 
as an AE or SAE. Any SAE occurring in association with a pregnancy, brought to the 
Investigator’s attention after the subject has completed the study and considered by the 
Investigator as possibly rela ted to the study treatme nt, m
ust be promptly reported to 
Indivior or designated represen tative. While the Investigator is not obligated to actively 
seek this information in former study subjects, he or she may learn of a pregnancy 
through spontaneous reporting.  
12.2 Action to be Taken if Pregnanc y Occurs in a Female Subject  
If a female subject suspects that she is pregnant (e.g., missed period, self-administered 
pregnancy test) between scheduled  visits, the subject will be asked to return to the clinic 
at the next scheduled visit. Removal of the SUBLOCADE depot will not be required if 
pregnancy occurs. 
If a urine pregnancy test duri ng a subject’s visit confirms th at a subject is pregnant, the 
subject will receive no further injections, a nd the current visit will be considered the 
subject’s ET Visit. If the subject any ongoing AEs or concom itant medications at the ET 
Visit, she will also be followed up by telephone 4 weeks later for the safety follow up to 
assess the ongoing AEs or concomitant medications only. 
The Investigator should fully inform the female subject of the potential risk to the foetus.  
13 DATA MANAGEMENT 
13.1 Data Collection and Management  
Data will be entered onto a CRF and will be  managed in accordance with the data 
management plan to ensure th at the integrity of the data is maintained. Adverse events 
will be coded using the Medical Dictiona ry for Regulatory Activities (MedDRA).. 
Subject identifiers will not be collected or tr ansmitted to Indivior according to Indivior 
standards and procedures. Data collection will be completed according to the study plans.  
13.2 Database Quality Assurance  
The CRFs will be reviewed and checked for omissions, apparent errors and values 
requiring further clarification using manua l procedures. Data queries requiring 
clarification will be generated and addressed by the investigational site. Only authorized 
personnel will make corrections to the CRFs, and all corrections will be documented in 
an audit trail. 
13.3 Source Documentation 
The Investigator is responsibl e for the quality of the data recorded in the CRF. The data 
recorded should be a complete and accurate  account of the subject’s record collected 
during the study.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 41 of 52 
 
  
  
 Study data will not be recorded solely onto the CRF but will be in itially documented in 
source documents.  Sour ce docum
ents may be el ectronic, hard copy, or a combination of 
both and are defined as the results of origin al observations and activ ities of a clinical 
investigation. Source documents will include , but are not limited to, progress notes, 
electronic data, screenin g logs and recorded data from au tomated instruments. All source 
documents pertaining to this study will be maintained by the Investigator and made 
available for direct inspection by the authorized study personnel. 
14 STATISTICS 
This section describes sample size determ ination, analysis populations and planned 
analyses for safety measures.  
14.1 General Procedures 
All safety data will be listed. 
Continuous variables will be summarised us ing descriptive statis tics such as mean, 
standard deviations (SD), me dian, minimum and maximum. Ca tegorical variables will be 
reported as frequency counts (including number missing) and the percentage of subjects 
in corresponding categories. Indi vidual subject data will be presented by subject in data 
listings. Data listings will include all data colle cted from the initial screening visit to the 
safety follow up for all subjects enrolled. A statistical analysis plan (SAP) will be 
prepared after the protocol is approved a nd before database lock occurs. The SAP will 
provide further details regarding analysis . Additional unplanned analyses may be 
required after all planned analyses have been completed. Any deviations from the 
analyses described below will be outlined in the SAP. Any unplanned analyses will be 
clearly identified in the clinical study report. 
14.2 Sample Size 
Up to 25 adult subjects with moderate to severe OUD are planned to be enrolled onto the 
study.  
14.3 Analysis Populations 
The Safety population will consist of all subjects who received at least 1 dose of 
SUBLOCADE, and will be the pr imary population for all analyses 
14.4 Analysis of Primary, Secondary  and Exploratory Endpoints 
14.4.1 Primary Endpoint 
All TEAEs collected during the treatment period will be presented by system organ class 
and preferred term, each in descending order of frequency, unless otherwise specified.  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 42 of 52 
 
  
  
 A TEAE is defined as an AE observed afte r starting administration of SUBLOCADE in 
this study. If subject experiences an event both prior to starting administration of 
SUBLOCADE and ongoing during the treatment, the ev
ent will be considered a TEAE 
(of the treatment) only if it has worsened in se verity (i.e., it is reported with the date of 
worsening as the new start date/time) afte r starting administration of SUBLOCADE in 
this study. 
Adverse events will be coded using the most up-to-date version of the 
MedDRA dictionary and grouped by primary system organ class. The Investigator 
determines the intensity of AEs and th e relationship of AEs to study therapy.  
14.4.2 Analysis of Other Safety Data 
Drug-related TEAE, serious TEAE, drug-rela ted serious TEAE and TEAE leading to 
treatment discontinuation will be summarised by system organ class and preferred term. 
Other safety data will be analysed using descriptive statistics fo r continuous endpoints 
(e.g., n, mean, median, SD, minimum and ma ximum) and frequency counts with 
percentages for discrete endpoints. Complete  details of the safety analyses will be 
provided in the SAP. 
14.4.3 Other Safety Variables    
The results of scheduled assessments of pregnancy tests and concomitant medications 
will be  listed. Further details will be provided in the SAP. 
Substance/drug use, detox and MOUD treatm
ent history will be summar ized and listed.  
14.5 Demographic and Baseline Characteristics 
Demographic and disease charac teristics at screening, (e.g., ag e, gender, race, ethnicity, 
weight, height, Body Mass index (BMI), tobacco use, alcohol use and illicit drug use, 
baseline disease history) will be summarised using descriptive statistics. Qualitative 
variables, (e.g., gender, race) will be su mmarised using freque ncies; quantitative 
variables, (e.g., age, weight, height) will be summarised using (n, mean, SD, median, 
minimum and maximum). 
14.6 Interim Analysis 
No formal interim analyses are planned for this study. 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 43 of 52 
 
  
  
 15 ETHICS AND RESPONSIBILITIES 
15.1 Good Clinical Practice 
Prior to site activ ation, Indivior o
r designated representative will obtain 
approval/favourable opinion from the releva nt regulatory agency (ies) to conduct the 
study in accordance with ICH/GCP and any applicable country-specific regulatory 
requirements.  
The study will be carried out in accordance to  the protocol and with local legal and 
regulatory requirements, ICH/ GCP and all applicable subject privacy requirements. 
15.2 Data and Safety Monitoring Committee 
There will be no data and safety monitoring committee for this study.  
15.3 Institutional Review Board/I ndependent Ethics Committee 
The protocol, ICF(s) and any other written info rmation and/or material s to be provided to 
subjects will be reviewed by an independent  and appropriately c onstituted IRB. If 
required by local regulations, the protocol should be re-approved by the IRB annually. 
The IRB must be constituted and operate  in accordance with the principles and 
requirements of ICH/GCP.  
Study drug can only be released to the Invest igator after documentation that all ethical 
and legal requirements for starting the study ha s been received by I ndivior or designated 
representative. 
15.4 Informed Consent 
The Investigator or a person designated by the Investigator (if allowed by local 
regulations) is to obtai n written informed consent from e ach subject prior to entering the 
study. All written informed consent documents are required to have been reviewed and 
received a favourable opinion/approval from  an IRB prior to presenting them to a 
potential participant.  
Any changes to the ICF must be reviewed by Indivior before submission to the IRB.  
The written informed consent process will include the review of oral and written 
information regarding the purpose, methods, anticipated duration and risks involved in 
study participation. The Investigator is to  ensure that each subject is given the 
opportunity to ask questions and allowed time to consider the information provided. The 
Investigator or a person designated by the Investigator must also explain to each subject 
that participation is voluntar y, and that consent can be wit hdrawn at any time and without 
reason. Subjects will receive a signed and date d copy of the signed ICF before any study-
specific procedures are conducted.   
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 44 of 52 
 
  
  
 In the event that new safety information emerges that represents a significant change in 
the risk/benefit assessment, the signed IC F should be updated accord ingly. All subjects 
should be infor
med of the new information, provide their consent to continue in the 
study, and be provided with a signed and dated copy of the revised signed ICF.  
15.5 Study Files and Record Retention 
The Investigator must mainta in all study-related records (except for those required by 
local regulation to be maintained elsewhere) in a safe a nd secure location throughout the 
conduct and following the closure of the st udy. The records must be accessible upon 
request (e.g., for an IRB, Indi vior or regulatory inspection)  along with the facility, study 
personnel and supporting systems/hardware. All documents pertaining to the study, 
including all versions of the approved study protocol, copy of the ICF and other 
documents as required per local laws and re gulations (e.g., Health Insurance Portability 
and Accountability Act [HIPAA] documents), completed CRFs, source records (subject 
records, subject diaries, hospital records, laboratory records, drug accountability records, 
etc.), and other study-related materials will be retained in the permanent archives of the 
study site.  
Where permitted by local laws and regulations , records may be maintained in a format 
other than hard copy (e.g., electronically in an electronic medical records system). The 
Investigator must ensure that all reproductions are an accurate legible copy of the original 
and that they meet necessary accessibility and retrieval stan dards. The Investigator must 
also ensure that a quality control process is in place for making reproductions and that the 
process has an acceptable back-up of any reproductions.  
The minimum retention time for retaining st udy records will be in accordance with the 
strictest standard applicable for the study site  as determined by local  laws, regulations or 
institutional requirements. If the Investigat or withdraws from the study (e.g., relocation, 
retirement) all study-related records should be  transferred, in a written agreement with 
Indivior, to a mutually agreed upon designee within Indivior-specified time frame. 
16 AUDITING AND MONITORING 
The purpose of an audit or regulatory inspection is to verify the accuracy and reliability 
of clinical study data submitted to a regulatory authority in support of research or 
marketing applications, and to assess complia nce with statutory requirements regulations 
governing the conduct of c linical studies.   
In accordance with applicable regulations, GC P and Indivior procedures, the clinical 
monitor(s) will periodically co ntact the site, including conducting on-site visits at 
intervals agreed by the Inves tigator and documented in the Clinical Monitoring Plan and 
the Site Initiation Visit Report.  
The clinical monitor(s) will cont act the site prior to the star t of the study to discuss the 
protocol and data collection procedures with site personnel. In accordance with 
applicable regulations and GCP guidelines, th e Investigator shall make available for 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 45 of 52 
 
  
  
 direct access all study-related records upon request  by Indivior, Indivio r’s agents, clinical 
monitor(s), auditors and/or IRB. The mon itors will visit the site during the study in 
addition to maintaining frequent telephone  and written communication. The extent, 
nature, and frequency of on-site visits will be based on such consideration s
 as the study 
objectives and/or endpoints, the purpose of the study, study design complexity and 
enrolment rate.  
The Investigator must allow the clinical monitor(s) direct acc ess to all relevant 
documents and to allocate his/her time and th e time of his/her staff to the clinical 
monitor(s) to discuss findings  and any relevant issues.  
Upon completion of the study, st udy closeout activities must be conducted by Indivior or 
its designee in conjunction with th e Investigator, as appropriate.  
Steps to be taken to ensure the accuracy and reliability of data in clude the selection of 
qualified Investigators a nd appropriate study sites, review of  protocol procedures with the 
Investigators and associated personnel befo re the study, periodic monitoring visits by 
Indivior, and direct transmission of clinical laboratory data from a central laboratory into 
Indivior’s (or designee’s) database. Written instructions will be provided for study drug 
preparation and dosing, collection, preparati on and shipment of blood, plasma and urine 
samples. Guidelines for CRF completion wi ll be provided and reviewed with study 
personnel before the start of the study. Indivior (or designee) will review CRFs for 
accuracy and completeness during on-site mon itoring visits and after transmission to 
Indivior (or designee). Any di screpancies will be resolved with the Investigator or 
suitably qualified designee,  as appropriate.  
This study will be organised, performed and reported in compliance with the protocol, 
SOPs, working practice documents and app licable regulations and guidelines.  
In accordance with the standards defined in Indivior SOPs and applicable regulatory 
requirements, clinical studies sponsored by Indivior are subject to Indivior Quality 
Assurance (QA) Investigator Site Audits that  may be delegated to a contract research 
organisation or Indivior contract auditors. Investigator Site  Audits will include review of, 
but are not limited to, drug supply, presence of  required documents, the informed consent 
process and comparison of CRFs with sour ce documents. The Investigator agrees to 
participate with audits conducted at a r easonable time in a reasonable manner. Full 
consultation with the Investigator will be ma de prior to and during such an audit, which 
will be conducted according to Indivior’s or a contract research organisation’s QA SOPs. 
In addition, this study is subj ect to inspections by Regulat ory Authorities. If such a 
regulatory inspection occurs, the Investigator agrees to allow the regulatory inspector 
direct access to all relevant study documents. The Investigat or must contact Indivior 
immediately if this occurs and must fully cooperate with the in spection conducted at a 
reasonable time in a reasonable manner. 
  
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 46 of 52 
 
  
  
 17 AMENDMENTS 
Protocol modifications, except those intended to reduce immediate ri sk to study subjects, 
may be made only by Indivior. A protocol ch ange intend ed to elim
inate an apparent 
immediate hazard to subjects may be impl emented immediately, provided the IRB is 
notified within 5 days.  
Any permanent change to the protocol must be handled as a prot ocol amendment. The 
written amendment must be submitted to the IRB and the Investigator must await 
approval before implementing the changes. Indi vior or designated representative will 
submit substantial protocol amendments to the appropriate Regulatory Authorities for 
approval.  
If in the judgment of the IRB, the Investig ator and/or Indivior, the amendment to the 
protocol substantially changes the study design and/or increases the potential risk to the 
subject and/or has an impact on the subject ’s involvement as a study participant, the 
currently approved written ICF will require si milar modification. In such cases, informed 
consent will be renewed for subjects enrolled in the study before continued participation, 
based on IRB determination. 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 47 of 52 
 
  
  
 18 STUDY REPORT AND PUBLICATIONS 
A clinical study report will be prepared following  com
pletion of the study. An 
Investigator signatory may be identified fo r the approval of the report if required by 
applicable regulatory requirements.  
The study data will be owned by Indivior. Pub lication of any and all data will be at the 
discretion of Indivior. The Investigator will not disseminate, present or publish any of the 
study data without the prior written approval from Indivior to do so. 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 48 of 52 
 
  
  
 19 STUDY DISCONTINUATION  
Both Indivior and the Inves tigator reserve the right to terminate the study at the 
Investigator’s site at any time. Should this be  necessary, Indivior, or a specified designee 
will inform the appropriate Regulatory Authorit ies of the terminati on of the study and the 
reasons for its term inatio
n, and the Investigator will inform the IRB of the same. In 
terminating the study, Indivior and the I nvestigator will assure that adequate 
consideration is given to the prot ection of the subjects’ interests. 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 49 of 52 
 
  
  
 20 CONFIDENTIALITY 
All subject-identifying documentation generated in this study is confidential and may not 
be disclosed to any persons not directly  concerned with the study without written 
permission from the subject. However, aut horized regulatory offi cials and Indivior 
personnel (or their repres entatives
) will be  allowed full access to inspect and copy the 
records. All subject bodily fluids and/or other materials collected sha ll be used solely in 
accordance with this protocol and the ICF si gned by the subject, unless otherwise agreed 
to in writing by Indivior.  
Each subject will be identified assigned s ubject number when reporting study information 
to any entity outside of the study centre. Data  containing subject iden tification will not be 
removed from the clinic without fi rst redacting subj ect identifiers. 
 
16.1.1 Protocol Amendment 1 
INDV-6000-4
04 - SUBLOCADE Rapid Initiation Extension Stud y Confidential  
SUBLOCADE™ (extend
ed-release buprenorphine) Page 50 of 52 
 
  
  
 21 REFERENCES 
Cytochrome P450 3A4 and 2C8 inhibitors and inducers, 
http://medicine.iupui.edu/clinpharm/ddis/clinical-table/ , Accessed 08 July 2019 
Kamp m
an K, Jarvis M. ASAM National Practic e Guideline for the Use of Medications in 
the Treatment of Addiction involving Opioid Use. J Addict Med. 2015, 9:358-67. 
SUBLOCADE™ (extended-releas e buprenorphine) injection, fo r subcutaneous (SC) use 
(CIII) USPI. Indivior; March 2018. 
Substance A
buse and Mental Health Servi ces Administration (SAMHSA). Center for 
Substance Abuse Treatment. Treatment Impr ovement Protocol (TIP) 63, Medications for 
Opioid Use Disorder. HHS Publication No. (SMA) 18-5063. 2018. 
Substance Abuse and Mental Health Services Administration. Clinical Guidelines for the 
Use of Buprenorphine in the Treatment of  Opioid Addiction. Treatment Improvement 
Protocol (TIP) Series. C. f. S. A. Treatment.40. 2004. 
Tompkins DA, Bigelow GE, Harrison JA, Johns on RE, Fudala PJ, Strain EC. Concurrent 
validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices 
against the Clinical Institute Narcotic Asse ssment (CINA) opioid withdrawal instrument. 
Drug Alcohol Depend. 2009;105(1-2):154-9. 
Wiest K, Algera MH, Moss L, van Velzen M, Dobbins R. High Pl asma Buprenorphine 
Concentrations Decrease Respiratory Effects of Intravenous Fentanyl. 50th Annual 
ASAM Conference. 2019.  
 